Clinical trial · no report yet · Phase 2
IFM 2018-04
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
- NCT03606577 ↗
- Active not recruiting
- Nantes University Hospital
- 15 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| YouTube | 5 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients: a Phase II Study of the Intergroupe Francophone du Myélome "IFM 2018-04"
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib; Daratumumab; Lenalidomide; Dexamethasone
- Arms
- Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone · Experimental
- Enrollment
- 50 (estimated)
- Primary outcomes
- Percentage of patients receiving the second Autologous Stem Cell Transplant
- Sponsor
- Nantes University Hospital
- Start
- Jul 30, 2019
- Primary completion
- Feb 8, 2022 (estimated)
- Results posted
- No
- Registry record
- NCT03606577 · updated Apr 28, 2021
Publications
linked from the registry- Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Chretien ML, Karlin L, Escoffre M, Jacquet C, Tiab M, Leleu X, Avet-Loiseau H, Jobert A, Planche L, Corre J, Moreau P. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 2024 May 16;143(20):2029-2036. doi: 10.1182/blood.2023023597. PubMed 38394666
- Pawlyn C. High-risk myeloma: a challenge to define and to determine the optimal treatment. Lancet Haematol. 2021 Jan;8(1):e4-e6. doi: 10.1016/S2352-3026(20)30361-6. Epub 2020 Dec 22. No abstract available. PubMed 33357481